section_path: Management/Medications/Long–term control
section_name: Long–term control
paragraph_text: Long–term control
  
  For children with asthma which is well-controlled on combination therapy of inhaled corticosteroids (ICS) and long-acting beta -agonists (LABA), the benefits and harms of stopping LABA and stepping down to ICS-only therapy are uncertain. In adults who have stable asthma while they are taking a combination of LABA and inhaled corticosteroids (ICS), stopping LABA may increase the risk of asthma exacerbations that require treatment with corticosteroids by mouth. Stopping LABA probably makes little or no important difference to asthma control or asthma-related quality of life. Whether or not stopping LABA increases the risk of serious adverse events or exacerbations requiring an emergency department visit or hospitalisation is uncertain.